Christopher Becker, Ph.D. Joins SurroMed as Director of Chemistry and Mass Spectrometry
Mountain View, Calif./ September 4, 2001 / - SurroMed, Inc. today announced that Christopher Becker, Ph.D., has joined the company as director of chemistry and mass spectrometry. Dr. Becker is an internationally renowned expert in mass spectrometry of biomolecules and will lead SurroMed's efforts in proteomics and orgeomics (the study of low molecular weight organic compounds such as peptides, lipids and sugars) for improved and enhanced drug discovery and development.
Dr. Becker, 49, has worked in the field of mass spectrometry for over 20 years, most recently as senior director of proteomic technology at ThermoFinnigan Corp. Prior to that, Dr. Becker was co-founder and chief technology officer of GeneTrace Systems. He received his Ph.D. from the University of California at Berkeley and did his postdoctoral training at Massachusetts Institute of Technology. He is the author of over 100 peer-reviewed publications.
"Mass spectrometry is a definitive technique for the analysis of trace organic compounds and the cornerstone of SurroMed's proteomic and orgeomic technologies," said Gordon Ringold, Ph.D., SurroMed's co-founder, chairman and chief executive officer. "Under Chris' leadership we will further develop our mass spectrometry-based technologies that are valuable to SurroMed's integrated set of phenotyping technologies, enabling more precise diagnosis and treatment of human disease."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic compounds (such as sugars, peptides and lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Executive
(415) 677-4455 ext.284
email: [email protected]
Dr. Becker, 49, has worked in the field of mass spectrometry for over 20 years, most recently as senior director of proteomic technology at ThermoFinnigan Corp. Prior to that, Dr. Becker was co-founder and chief technology officer of GeneTrace Systems. He received his Ph.D. from the University of California at Berkeley and did his postdoctoral training at Massachusetts Institute of Technology. He is the author of over 100 peer-reviewed publications.
"Mass spectrometry is a definitive technique for the analysis of trace organic compounds and the cornerstone of SurroMed's proteomic and orgeomic technologies," said Gordon Ringold, Ph.D., SurroMed's co-founder, chairman and chief executive officer. "Under Chris' leadership we will further develop our mass spectrometry-based technologies that are valuable to SurroMed's integrated set of phenotyping technologies, enabling more precise diagnosis and treatment of human disease."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic compounds (such as sugars, peptides and lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Executive
(415) 677-4455 ext.284
email: [email protected]